Laura Sena
laurasenamd.bsky.social
Laura Sena
@laurasenamd.bsky.social
Physician-scientist and prostate cancer medical oncologist at Johns Hopkins
We are excited to open a clinical trial to assess how metabolic changes induced by water-only fasting affects the immune response to prostate cancer. Spread the word – I’m happy to discuss with any interested candidates. clinicaltrials.gov/study/NCT068...
ClinicalTrials.gov
clinicaltrials.gov
May 22, 2025 at 9:32 PM
Reposted by Laura Sena
Thrilled to share a project that we envisioned over a decade ago to perform high purity/high specificity molecular analysis of circulating tumor cells! Led by the Dr. Marina Sharifi and Dr. Jamie Sperger and funded by Funded by PCF, NCI, DOD @theaacr.bsky.social urldefense.com/v3/__https:/...
February 6, 2025 at 7:32 PM
Reposted by Laura Sena
The AACR is deeply concerned that the Administration’s recent actions are threatening NIH and its mission to accelerate progress for patients with cancer and other diseases that afflict millions of Americans. Read our statement: https://buff.ly/4gRXNB8
February 18, 2025 at 6:09 PM
Reposted by Laura Sena
But…..ok, ok, I’m convinced. Elegant and definitive.
www.science.org/doi/10.1126/...
Metformin targets mitochondrial complex I to lower blood glucose levels
Acute oral metformin administration lowers blood glucose levels by targeting mitochondrial complex I.
www.science.org
December 23, 2024 at 2:36 PM
Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer https://www.medrxiv.org/content/10.1101/2024.12.12.24318845v1
December 13, 2024 at 9:36 PM
Reposted by Laura Sena
Fascinating and well written! Reminiscent of a patient from our rapid autopsy cohort with targetable truncal driver but remarkable “dead-end” CNA-quiet subclones in the primary that fail to metastasize despite aggressive histology.

pubmed.ncbi.nlm.nih.gov/34568716/
December 9, 2024 at 8:09 PM
Happy to share an educational case that demonstrates that selection can drive acquired therapy resistance in metastatic prostate cancer rdcu.be/d15Ph Wonderful collab with @rachelkarchin.bsky.social @davidesanin.bsky.social
Intratumoral heterogeneity drives acquired therapy resistance in a patient with metastatic prostate cancer
npj Precision Oncology - Intratumoral heterogeneity drives acquired therapy resistance in a patient with metastatic prostate cancer
rdcu.be
December 9, 2024 at 6:15 PM
Thanks for visiting and teaching us amazing science Nima!!
Had amazing time as Visiting Professor ⁦‪at Johns Hopkins! Equal parts fun talking science, seeing friends, making new ones, crashing the prostate research group’s holiday party & spotting photo of ⁦‪⁦‪⁦Mark Gonzalgo’s residency photo‬⁩. Grateful to Karen Sfanos and the Kimmel Cancer Center!
December 7, 2024 at 1:14 AM